For example, a VEGF inhibitor may be most optimal agent to be administered to patients with uncontrolled diabetes mellitus or active lung disease, while an mTOR inhibitor could be the suitable choice in patients with uncontrolled arterial hypertension, cardiac history, or high risk of hemorrhage. This evidence concerns the gene VEGFA and Hypertension.